3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
3
Radiation Injuries
1
Prostatic Neoplasms
1
Neoplasms, Second Primary
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Eye Diseases
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Cardiovascular Diseases
1
Interventions
Docetaxel
158
Prednisone
131
Leuprolide
95
bicalutamide
86
enzalutamide
83
Radiotherapy
80
Goserelin
80
Abiraterone Acetate
76
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
54
Magnetic Resonance Spectroscopy
46
Zoledronic Acid
44
gallium 68 PSMA-11
37
Flutamide
34
abiraterone
32
Estramustine
32
radium Ra 223 dichloride
30
apalutamide
27
Surveys and Questionnaires
26
Gonadotropin-Releasing Hormone
26
Androgen Antagonists
25
cabazitaxel
24
Radiosurgery
24
Dutasteride
22
sipuleucel-T
21
Prednisolone
21
Triptorelin Pamoate
20
Paclitaxel
20
luprolide acetate gel depot
19
Radiation
19
Exercise
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Prostatic Neoplasms
×
beta Carotene
×
Clear all
NCT00270647
2018-02-28
PHS II
Brigham and Women's Hospital
Phase NA
Completed
14,641 enrolled